In overweight or obese adults with type 2 diabetes in the integrated data platform with dietary management group, those who also used semaglutide achieved the largest weight loss, 13.4% after 12 weeks.
In plain wordsIn overweight or obese adults with type 2 diabetes using a data platform and diet management, those also using semaglutide lost the most weight.
- Peptide
- Semaglutide
- Outcome
- DecreaseWeight loss at 12 weeks in overweight or obese patients using semaglutide in the platform group
- Study
n: not reported in source
- Outcome group
- Body weight · Metabolic and weight
Measurements
- Weight loss
- 13.4%
- platform plus diet plus semaglutide, 12 weeks
Source sentences
Those overweight or obese patients in the experimental group utilizing the appetite suppressant semaglutide achieved the most significant weight loss, with a 13.4% reduction after 12 weeks.
1 context sentence(design, population, supporting numbers)
One hundred eighty patients with type 2 diabetes were randomly allocated into a control group (Group A) and an experimental group (Group B).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.